HIV/AIDS Clinical Trials

Find HIV/AIDS Clinical Trials Near You

Stick2PrEP Women/Trans Individuals: Increasing Pre-Exposure Prophylaxis (PrEP) Uptake, Adherence, and Retention in Care, and Understanding PrEP Preferences Among Predominantly Black and Latinx Cisgender Women and Transgender Individuals

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Taking a daily anti-HIV pill can protect people from HIV infection. This is called preexposure prophylaxis \[PrEP\]. Many cisgender women and trans individuals do not know this medication is available; others struggle to take the pill every day. It is important to understand attitudes and preferences about HIV prevention options, especially as new options become available. This study plans to evaluate preferences over time among cisgender women and trans individuals who are taking medication to prevent HIV, and among cisgender women and trans individuals who are not taking medication but are at risk of HIV. The investigators enroll up to 175 participants who visit the HIV prevention clinic, and the investigators will ask participants to complete questionnaires at regular follow up visits and between visits. This study may help the investigators understand how best to prevent HIV among people at risk.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Cisgender women and trans individuals who have an indication for PrEP and have 1) decided to take PrEP, 2) decided not to take PrEP, or 3) decided to discontinue PrEP

Locations
United States
New York
Columbia University Medical Center
RECRUITING
New York
Contact Information
Primary
Deborah Theodore, MD
dat2132@cumc.columbia.edu
2123052201
Time Frame
Start Date: 2021-10-25
Estimated Completion Date: 2026-10-25
Participants
Target number of participants: 175
Treatments
Other: Cisgender Women and Trans Individuals (CWTI)
Cisgender women and trans individuals (CWTI) who are taking PrEP, have considered and decided not to take PrEP, or who have discontinued PrEP.
Related Therapeutic Areas
Sponsors
Leads: Columbia University
Collaborators: Merck Sharp & Dohme LLC

This content was sourced from clinicaltrials.gov